Almost certainly yes, and the specific requirements depend entirely on which body certifies you. This article will not tell you what your rule is, because the rules differ between certifying authorities, they have changed over the past few years, and getting this wrong from an article rather than from your examiner is the expensive version of the mistake.<\/p>\n
What it will do is explain why you cannot look this up generically, what to ask, and who to ask.<\/p>\n
Different authorities regulate different roles, and they take different approaches.<\/p>\n
Aviation medical certification<\/strong> has specific, published requirements for GLP-1 medications, including observation periods and grounding after dose changes. If you are a pilot, those details matter and they are worth reading properly. Our guide on what pilots need to know about Ozempic and FAA rules<\/a> covers that specific framework.<\/p>\n Commercial driving certification<\/strong> works differently. The federal framework for commercial drivers is built around medical conditions and functional capability rather than around lists of named medications, and its public materials do not address GLP-1 medications specifically. That absence is not permission. It means the judgment sits with your medical examiner, applying the general standards to your situation, which is precisely why you have to ask rather than look it up.<\/p>\n Military and other service roles<\/strong> have their own policies, which vary by branch and by role and have been actively changing.<\/p>\n Other safety-sensitive certifications<\/strong> including maritime, rail, and various licensed trades each have their own arrangements.<\/p>\n Two people in different jobs on the same medication can face genuinely different requirements. That is why a forum answer is worthless here even when it is confidently given.<\/p>\n Understanding this makes the conversation with your examiner more productive.<\/p>\n The issues regulators tend to care about with this drug class are not exotic. They are the side effects: nausea and vomiting, the risk of dehydration, fatigue, and in people also taking certain diabetes medications, the possibility of low blood sugar. Those matter more in a role where becoming suddenly unwell has consequences for other people.<\/p>\n Dose changes are the other focus, because that is when side effects concentrate. Several frameworks treat a period after starting or increasing differently from a stable maintenance dose, and that pattern reflects the clinical reality rather than bureaucracy.<\/p>\n Our comparison of tirzepatide and semaglutide side effects<\/a> covers what is typical and when.<\/p>\n Note the order. Your prescriber is on the list and is not at the top of it, because they know your medicine and your examiner knows your certification.<\/p>\n Your examiner will generally want to know:<\/p>\nWhat actually drives the concern<\/h2>\n
Who to ask, in order<\/h2>\n
\n
What to have ready<\/h2>\n
\n